Navigation Links
Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers

se 2 Trials

Poniard anticipates initiating the Phase 2 components of the CRC and HRPC trials in the third quarter of 2007.

The Phase 2 CRC trial will include patients newly diagnosed with metastatic disease and will evaluate the safety and efficacy of picoplatin when combined with fluorouracil and leucovorin (FOLPI) and administered biweekly compared with oxaliplatin (Eloxatin(R)) at 85 mg/m2 combined with fluorouracil and leucovorin (FOLFOX). The objective of this multi-center, double-blind, randomized Phase 2 CRC trial of approximately 140 patients is to demonstrate that picoplatin is a neuropathy-sparing platinum that has an improved side effect profile compared to oxaliplatin, enabling a larger randomized Phase 3 CRC trial that has the potential to demonstrate superior safety and efficacy compared to FOLFOX.

The objective of the Phase 2 HRPC trial is to position picoplatin as the preferred platinum in combination with docetaxel plus prednisone and improve on the efficacy of docetaxel as a single agent plus prednisone. This multi- center, open-label, single-arm trial of approximately 30 patients is designed to demonstrate superior efficacy when picoplatin is administered with docetaxel plus prednisone every three weeks in the first-line setting.

About Picoplatin

Picoplatin, the Company's lead product candidate, is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. In addition to the ongoing Phase 1/2 clinical trials of intravenous picoplatin in CRC and HRPC, Poniard is evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial in small cell lung cancer (SCLC). On May 1, 2007, the Company announced treatment of the first patient in its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of intravenous picoplatin in SCLC, which is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA). Poniard re
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:12/22/2014)...   TRU-D SmartUVC LLC, producers of the ... today that the General Services Administration has awarded the ... This newly formed agreement will allow TRU-D ... purchasers, including Department of Veteran Affairs and Department of ... purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)... Dec. 22, 2014  ConvaTec, a privately-held medical products ... been appointed Interim Chief Executive Officer of the company, ... Ken Berger .  "The Board of Directors of ... ConvaTec over the past three years," said Magnus ... "We are confident that the company is well positioned ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
(Date:12/24/2014)... 24, 2014 The 2014 Market ... professional and in-depth research report on COC industry. ... basic information, including its definition, classification, application, industry ... etc. This report also presents product specification, manufacturing ... separated by regions, technology and applications. Analysis also ...
(Date:12/24/2014)... Plantation, FL (PRWEB) December 24, 2014 ... permanent solution for a tooth replacement. They offer the ... boast several advantages over other forms of tooth replacement. ... not rely on the adjacent teeth for support, and ... many people have been told that they are not ...
(Date:12/24/2014)... Dr. Ronald Receveur, a New Albany ... dental implants in a day, has written a ... teeth-whitening treatments. , In his blog published Dec. ... writes that overusing teeth-whitening treatments can lead to tooth ... , “Because teeth-whitening treatments are available in ...
(Date:12/24/2014)... Dec. 23, 2014 (HealthDay News) -- Longer and colder body ... who have brain damage from a lack of oxygen, a ... in newborns with this condition -- called hypoxic ischemic encephalopathy ... 33.5 degrees Celsius (92.3 Fahrenheit) for 72 hours, experts say. ... the brains of animals, so this study examined if the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Tri-City Medical Center in Oceanside, Calif. The top ... B. E. Smith has recently placed more than 900 ... is a community owned, 397-bed, Gold Seal-approved, full-service acute-care ...
Breaking Medicine News(10 mins):Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 3Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3
... new study published in the journal Ultrasound in Obstetrics ... infant survival rate in severe cases of congenital diaphragmatic hernia ... a severe malformation (hole) of the diaphragm and is a ... an incomplete development of the lungs. Researchers led by ...
... FOR DEC. 14, 2011] The two main ways to ... antiviral drugs. A team of investigators has found that ... complement these approaches and reduce mortality among patients hospitalized ... Journal of Infectious Diseases and are now available ...
... Dec. 13 (HealthDay News) -- An older woman,s sleep/wake cycle ... developing dementia, a new study suggests. It found that ... that sometimes precedes dementia) was higher in older women with ... more active later in the day, compared to those who ...
... fluid bathing the brain are linked to poor recovery ... University School of Medicine in St. Louis and the ... "We are particularly interested in finding ways to ... David L. Brody, MD, PhD, assistant professor of neurology ...
... 13, 2011 The American Cancer Society has revised ... consistency, and rigor in creating guidance about cancer ... from the Institutes of Medicine (IOM) by creating ... commissioning systematic evidence reviews, and clearly articulating the ...
... The U.S. Department of Justice filed a proposed consent ... requirements for three major tobacco companies to make internal ... the companies violated the Racketeer Influenced and Corrupt Organizations ... Tobacco Documents Library (LTDL). The order, once approved ...
Cached Medicine News:Health News:Statins may reduce mortality in patients hospitalized with influenza 2Health News:'Body Clock' Might Affect Women's Dementia Risk 2Health News:High levels of tau protein linked to poor recovery after brain injury 2Health News:High levels of tau protein linked to poor recovery after brain injury 3Health News:American Cancer Society revises cancer screening guideline process 2Health News:UCSF to receive tobacco papers, funding to improve public access to the documents 2
The TCM400 is the first and only portable instrument to provide up to six simultaneous measurements of transcutaneous oxygen tension (tcpO2)...
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2....
... the only online source of nationally accredited ... care nurses and other healthcare professionals., ,Radiometers ... you can take them at your convenience. ... is issued upon course completion. The curriculum ...
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
Medicine Products: